Hormone therapy for chronic disease prevention
Why flagged
Systemic HRT in an asymptomatic menopausal patient; chronic disease prevention use reversed by WHI 2002 and USPSTF 2022 (Grade D).
Estrogen or combined estrogen/progestin hormone therapy w…
Combined CEE+MPA increased CHD (HR 1.18), stroke (HR 1.31), and invasive breast cancer (HR 1.26; 95% CI 1.00-1.59). Estrogen alone increased stroke risk without CHD benefit.
Guidelines updated
USPSTF (2022): Grade D recommendation against the use of …
- Prior guidance2002
Estrogen or combined estrogen/progestin hormone therapy widely prescribed for cardioprotection and chronic disease prevention (Pre-2002 consensus).
- WHI2002
Combined CEE+MPA increased CHD (HR 1.18), stroke (HR 1.31), and invasive breast cancer (HR 1.26; 95% CI 1.00-1.59). Estrogen alone increased stroke risk without CHD benefit.
- Reversal2022
Guidelines updated
- Current recommendation
USPSTF (2022): Grade D recommendation against the use of systemic combined estrogen/progestin or estrogen alone for the primary prevention of chronic conditions.